Vinorelbine bitartrate injection

This drug is a semi-synthetic vinca alkaloid and a cell cycle-specific anticancer drug. The drug has similar effects to vincristine (VCR), mainly binding to tubulin to cause microtubule formation disorders in cells during mitosis; at high concentrations, this drug can also block cells from entering the M phase from the G★2★ phase. In addition to acting on mitotic microtubules, this drug also acts on axon microtubules, so it can cause neurotoxicity.

3’,4’-didehydro-4’-deoxy-8’-norvinblastine ditartrate, the molecular formula is C45H54N4O8·2C4H6O6, and the molecular weight is 1079.12.

It is clinically used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphoma, etc.

This product can only be administered intravenously. Monotherapy: The recommended dose is 25-30 mg per square meter per week; combined medication: Determined according to the treatment plan. This injection must be diluted with normal saline first, injected within a short period of time (6-10 minutes), and then the vein is flushed with 250-500 mL of normal saline. Instructions for use: The injection can only be started after the injection needle is confirmed to be in the vein. If the drug leaks out of the vein, it will cause a strong local irritation reaction. Once the drug leaks out, the injection should be stopped immediately, and the remaining drug should be injected into another vein. If the drug accidentally enters the eyes, it should be immediately rinsed with plenty of clean water or isotonic solution.

Hematologic toxicity: granulocytopenia, moderate anemia; peripheral neurotoxicity: generally limited to decreased deep tendon reflexes, numbness is rare, paresthesia is occasionally seen, and lower limb weakness may occur with long-term use; digestive tract autonomic nervous system: mainly constipation caused by intestinal paralysis, paralytic ileus is rare, and nausea and vomiting are occasionally seen; digestive system: may cause dyspnea or bronchospasm, which may occur within minutes or hours after injection; others: progressive moderate alopecia, mandibular pain, local phlebitis.

Patients with severe liver dysfunction, pregnant and lactating women.

·Drug-drug interactions 1. When used in combination with cisplatin, the incidence of granulocytopenia will increase. 2. Studies have shown that this drug can aggravate the mucosal toxicity of fluorouracil, especially when folinic acid is given at the same time. 3. It has been reported that when used in combination with mitomycin, pulmonary toxicity will be increased. 4. When using this drug, vaccination with live vaccines may increase the risk of infection with live vaccines, so vaccination with live vaccines is prohibited during medication. ·Drug-food interactions When taking this drug after a meal, its relative bioavailability will decrease by 22%±28%, and the peak time will be extended from 1.3 hours to 2.5 hours. If it is divided into two doses, its relative bioavailability will decrease by 16%±51%.

Store at 2~8°C away from light.

5 ml: 50 mg